CAR-T shows 'remarkable' efficacy as first-line therapy for large B-cell lymphoma
First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.An estimated 91% of patients treated with a single infusion of the chimeric antigen receptor T-cell therapy remained alive at 12 months, a primary analysis of the ZUMA-12 trial showed.